Novo after crucial data from competitor: Welcomes drug R&D

Investors in both Novo Nordisk and US firm Eli Lilly are highly satisfied with the results from Lilly's grand diabetes hope, tirzepatide. Novo Nordisk already has a potential new superdrug in its pipeline.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY BENJAMIN WERNER CHRISTENSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN

Things looked really great, but not to the extent that the firms have hit a home run.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading